# Semaglutide to Reduce Atrial Fibrillation Burden

Study · id `cardio:ct-nct05209165` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05209165](<https://clinicaltrials.gov/study/NCT05209165>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05209165

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 132 participants.

## Technical summary

Registry record NCT05209165. Randomized; quadruple masking; primary purpose treatment. Start 2023-05 (anticipated); primary completion 2027-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 132 participants (planned count; ClinicalTrials.gov record NCT05209165, source copy `cardio:ctgov-nct05209165-2022-10-27`, retrieved 2026-10-26)
- Planned start: 2023-05 (anticipated) (ClinicalTrials.gov record NCT05209165, source copy `cardio:ctgov-nct05209165-2022-10-27`, retrieved 2026-10-26)
- Primary completion: 2027-05 (anticipated) (ClinicalTrials.gov record NCT05209165, source copy `cardio:ctgov-nct05209165-2022-10-27`, retrieved 2026-10-26)
- Completion: 2028-05 (anticipated) (ClinicalTrials.gov record NCT05209165, source copy `cardio:ctgov-nct05209165-2022-10-27`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05209165, source copy `cardio:ctgov-nct05209165-2022-10-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "SUSPENDED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05209165-2022-10-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Semaglutide to Reduce Atrial Fibrillation Burden
- Condition: Atrial Fibrillation
- Condition: Obesity
- Condition: Overweight
- Intervention (Drug): Semaglutide
- Intervention (Drug): Placebo
- Lead sponsor: San Francisco Veterans Affairs Medical Center
- Lead sponsor class: FED

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)

## Provenance

Content hash: 5cba25dc2172e9b12404776baaf0be7d1b863530a912e4fc36c0d1a778a2ebdb
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
